Form 4: ClearPoint Neuro Director Matthew Klein Reports Stock Unit Conversion
SEC Form 4 Filing
Director Matthew Klein converted 17,153 restricted stock units into common stock on May 14, 2024.
Summary
- On May 14, 2024, Matthew B. Klein, a director of ClearPoint Neuro, Inc., converted 17,153 restricted stock units into common stock.
- The conversion was reported on a Form 4 filing with the SEC.
- Following the transaction, Klein directly owns 29,425 shares of common stock.
- The restricted stock units were granted on May 25, 2023, and vested on the earlier of the first anniversary of the grant date or the day immediately preceding the company's 2024 annual meeting of stockholders.
Sentiment
Score: 5
Explanation: This is a neutral event, reflecting a standard conversion of stock units. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This is a routine disclosure related to insider transactions and is a standard part of corporate governance.
Key Dates
| Date | Description |
|---|---|
| 05/25/2023 | Reporting person was granted 17,153 restricted stock units. |
| 05/14/2024 | Date of transaction: conversion of restricted stock units to common stock. |
| 05/15/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.